1. Prehn RT: Two competing influences that may explain concomitant tumor resistance. Cancer Res 53: 3266?3269, 1993
2. Allione A, Consalvo M, nanni P, Lollini PL, Cavallo F, Giovarelli M, Forni M, Gulino A, Colombo MP, Dellabona P, Hock H, Blankenstein T, Rosenthal FM, Gansbacher B, Bosco MC, Musso T, Gusella L, Forni G: Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with Interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumour necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and gamma interferon gene or admixed with conventional adjuvants. Cancer Res 54: 6022?6026, 1994
3. Hock H, Dorsch M, Kunzendorf U, Uberla K, Qin Z, Diamantstein T, Blankenstein T: Vaccinations with tumor cells genetically engineered to produce different cytokines: effectivity not superior to a classical adjuvant. Cancer Res 53: 714?716, 1993
4. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levisky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte macrophage colony stimulating factor stimulates potent, specific, and long lasting anti-tumor immunity. Proc Nat Acad Sci USA 90: 3539?3543, 1993
5. Forni G, Cavallo F, Consalvo M, Allione A, Dellabona P, Casorati G, Giovarelli M: Molecular approaches to cancer immunotherapy. Cytokines and Molecular Therapy 1: 225?248, 1995